Brian Higgins
- Oncology top 2%
- Cancer-related Molecular Pathways 17
- Cytokine Signaling Pathways and Interactions 5
- Colorectal Cancer Treatments and Studies 4
- Molecular Biology top 5%
- Melanoma and MAPK Pathways 7
- Angiogenesis and VEGF in Cancer 6
- PI3K/AKT/mTOR signaling in cancer 5
- Ubiquitin and proteasome pathways 5
- Cancer Research top 5%
- Biotechnology top 5%
- Hematology top 5%
-
- HIV/AIDS drug development and treatment 5
- Co-authors
- Kathryn PackmanKenneth KolinskyDavid HeimbrookChristian TovarZoran FilipovicHolly HiltonJames RosinskiLyubomir T. Vassilev
- Journals
- Molecular Cancer Therapeutics (5 papers)Cancer Research (5 papers)Investigational New Drugs (3 papers)
- Partner nations
- United StatesSwitzerlandCanada
In The Last Decade
Brian Higgins
38 papers receiving 2.9k citations
Hit Papers
Peers
Comparison fields: 5 of 100
- Oncology 1.7k
- Molecular Biology 2.0k
- Cancer Research 403
- Biotechnology 187
- Hematology 173
Countries citing papers authored by Brian Higgins
This map shows the geographic impact of Brian Higgins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Higgins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Higgins more than expected).
Fields of papers citing papers by Brian Higgins
This network shows the impact of papers produced by Brian Higgins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Higgins. The network helps show where Brian Higgins may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Brian Higgins, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 16 | |
| 2 | 2020 | 16 | |
| 3 | MDM2 inhibition: an important step forward in cancer therapybreakdown → | 2020 | 276 |
| 4 | 2019 | 13 | |
| 5 | 2017 | 84 | |
| 6 | 2014 | 50 | |
| 7 | 2014 | 42 | |
| 8 | Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Developmentbreakdown → | 2013 | 447 |
| 9 | 2011 | 62 | |
| 10 | 2011 | 170 | |
| 11 | 2011 | 38 | |
| 12 | 2011 | 10 | |
| 13 | 2010 | 23 | |
| 14 | 2010 | 307 | |
| 15 | 2009 | 25 | |
| 16 | Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapybreakdown → | 2006 | 553 |
| 17 | 2006 | 21 | |
| 18 | 2005 | 17 | |
| 19 | 2004 | 126 | |
| 20 | 1998 | 116 |
About Brian Higgins
Brian Higgins is a scholar working on Oncology, Genetics and Molecular Biology, having authored 38 papers that have together received 2.9k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (17 papers), Melanoma and MAPK Pathways (7 papers), Angiogenesis and VEGF in Cancer (6 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), Ubiquitin and proteasome pathways (5 papers), HIV/AIDS drug development and treatment (5 papers), Cytokine Signaling Pathways and Interactions (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). The work is most often cited by research in Oncology (1.7k citations), Molecular Biology (2.0k citations) and Cancer Research (403 citations). Brian Higgins has collaborated with scholars based in United States, Switzerland and Canada. Frequent co-authors include Kathryn Packman, Kenneth Kolinsky, David Heimbrook, Christian Tovar, Zoran Filipovic, Holly Hilton, James Rosinski, Lyubomir T. Vassilev, Ola Myklebost and Binh Thanh Vu. Their work appears in journals such as Molecular Cancer Therapeutics, Cancer Research, Investigational New Drugs, ACS Medicinal Chemistry Letters and Cancer Chemotherapy and Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.